|
Neoplasm Metastasis
|
|
0.080 |
GeneticVariation
|
BEFREE |
The disease-free interval from diagnosis of primary melanoma to first distant metastasis was shorter for patients with V600K compared with V600E melanoma (17.4 vs. 39.2 months, P = 0.048), with no difference in survival thereafter.
|
22535154 |
2012 |
|
Secondary Neoplasm
|
|
0.060 |
GeneticVariation
|
BEFREE |
Mutant allele-specific imbalance of the p.V600E mutation was predominantly present in specimens with distant organ metastases (79% versus 27% in LN metastases versus 13% in primary cutaneous tumors or adjacent soft tissue, P < .001). p.V600K was detected in 23% of men older than 60 years old, compared with 6% in women older than 60 years old and 2% in both men and women younger than 60 years old (P < .001).
|
25456393 |
2015 |
|
Secondary Neoplasm
|
|
0.060 |
GeneticVariation
|
BEFREE |
With regard to the B-raf protein sequence, the acidic amino acid transitions V599E and V599K were predicted in 15 (62%) and five (21%) of the 24 positive metastases, respectively.
|
16179870 |
2005 |
|
Secondary Neoplasm
|
|
0.060 |
GeneticVariation
|
BEFREE |
Interestingly, by droplet digital PCR, the V600E mutation was also detected in the first primary, and the V600K in the second primary and metastases.
|
30222690 |
2019 |
|
Secondary Neoplasm
|
|
0.060 |
GeneticVariation
|
BEFREE |
In this study, sensitive and quantitative BRAF V600E and V600K mutation-specific real-time quantitative PCR was used to study the occurrence of small subsets of mutation-positive cells in primary melanomas and melanoma metastases.
|
23499336 |
2013 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
Occult oncocytic papillary thyroid carcinoma with lymphoid stroma (Warthin-like tumor): report of a case with concomitant mutations of BRAF V600E and V600K.
|
26191315 |
2015 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
BRAF mutations were detectable in cfDNA in 76% and 81% of patients with BRAF V600E/V600K-positive tumors, respectively.
|
26446943 |
2016 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
The Idylla(™) System (Idylla(™)), i.e., the real-time-PCR-based Idylla(™) BRAF Mutation Test performed on the fully-automated Idylla(™) platform, enables detection of the most frequent BRAF V600 mutations (V600E/E2/D, V600K/R/M) in tumor material within approximately 90 min and with 1% detection limit.
|
26407762 |
2015 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
Compared with V600E, the presence of a V600K mutation was significantly associated with older age (median, 60.0 years vs 44.7 years; P < .001), male sex (80% vs 59%; P = .001), head/neck primary tumor location (30% vs 15%; P = .0026), shorter interval to stage IV disease (0.98 years vs 2.8 years; P = .015), and a shorter overall survival from the time of diagnosis of stage IV disease (median, 2.44 years vs 1.25 years; hazards ratio, 1.68 [P = .014]).
|
23922205 |
2013 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
Finally, the small sample size in V600K</span> tu</span>mors</span> is a major limitation of our study.
|
28858076 |
2017 |
|
Secondary Neoplasm
|
|
0.060 |
GeneticVariation
|
BEFREE |
In addition, a double mutation resulting in V599K substitution was detected in two suspect ocular metastases of cutaneous melanoma.
|
14522889 |
2003 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
Considered separately, BRAF V600E mutant melanomas were strongly associated with MSS independently of thickness and nodal status (HR 3.89, 95% CI 1.67-9.09; P < 0.01) but BRAF V600K</span> mutant tumours were not (HR 1.19, 95% CI 0.36-3.92; P = 0.77).
|
25752325 |
2015 |
|
Secondary Neoplasm
|
|
0.060 |
GeneticVariation
|
BEFREE |
Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
|
15935100 |
2005 |
|
Melanocytic nevus
|
|
0.020 |
GeneticVariation
|
BEFREE |
The BRAF V600E (c.1799T>A or c.1799_1800delTGinsA) and BRAF V600K mutations were detected in 85% (n = 34/40) of naevi.
|
28714107 |
2018 |
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
|
Cutaneous Melanoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In addition, a double mutation resulting in V599K substitution was detected in two suspect ocular metastases of cutaneous melanoma.
|
14522889 |
2003 |
|
leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
In a patient with a BRAF(V600K)-mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia.
|
24589925 |
2014 |
|
leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
Practical performance assessment employed 33 independent tissue samples, composed of 27 leukemias (by pyrosequencing: 8 wild-type; 18 mutated; 1 noninformative) and 6 melanomas (V600E; V600K; wild-type, 2 each).
|
25611237 |
2016 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.020 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
|
Unresectable Melanoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The U.S. Food and Drug Administration approved the use of trametinib and dabrafenib in combination for patients with metastatic or unresectable melanoma with BRAF V600K or V600E mutations-the first combination therapy approved for the disease.
|
24596183 |
2014 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.020 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
Unresectable Melanoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Recently, cobimetinib was approved for the treatment of metastatic or unresectable melanoma with serine/threonine-protein kinase B-raf (BRAF) V600E or V600K mutations when used in combination with the BRAF inhibitor vemurafenib.
|
28112278 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |